发布求助
文献互助 智能选刊 最新文献

International Journal of Hematologic Oncology最新文献

筛选
英文 中文
Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges. 除了意义不明的单克隆伽玛病之外，免疫球蛋白M伽玛病的临床谱:一个集中于诊断和管理挑战的病例系列。
International Journal of Hematologic Oncology Pub Date : 2023-06-01 DOI: 10.2217/ijh-2022-0006
Omer S Ashruf, Saeid Mirzai, Laeth L George, Faiz Anwer
{"title":"Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges.","authors":"Omer S Ashruf,&nbsp;Saeid Mirzai,&nbsp;Laeth L George,&nbsp;Faiz Anwer","doi":"10.2217/ijh-2022-0006","DOIUrl":"https://doi.org/10.2217/ijh-2022-0006","url":null,"abstract":"<p><p>Immunoglobulin M monoclonal gammopathy is detected in Waldenström macroglobulinemia (WM), a rare lymphoplasmacytic lymphoma with serum immunoglobulin M. We report three rare presentations with focus on diagnostic and management challenges of type I cryoglobulinemia, type II cryoglobulinemia, and Bing-Neel syndrome. In approximately 10% of WM cases, macroglobulins can precipitate to cryoglobulins. Type I and II cryoglobulinemia, representing 10-15% and 50-60% of WM cases, respectively, present with vasculitis and renal failure. Bing-Neel syndrome, representing 1% of WM patients, is a rare neurological complication with lymphoplasmacytic infiltration in the brain. WM diagnosis includes bone marrow biopsy, immunophenotypic analysis, and <i>MYD88</i> L265P mutation. We initiated management of cryoglobulinemia with dexamethasone, rituximab, and cyclophosphamide; in Bing-Neel, bortezomib and dexamethasone, followed by a Bruton tyrosine kinase inhibitor.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"12 2","pages":"IJH44"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9975884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia. 提高青少年和青壮年t细胞急性淋巴细胞白血病患者的生存率。
International Journal of Hematologic Oncology Pub Date : 2023-02-01 DOI: 10.2217/ijh-2022-0005
Amr Hanbali, Ahmed Kotb, Riad El Fakih, Feras Alfraih, Nahla Shihata, Walid Rasheed, Syed Osman Ahmed, Marwan Shaheen, Saud Alhayli, Ali Alahmari, Ahmad Alotaibi, Alfadel Alshaibani, Abdulwahab Albabtain, Mansour Alfayez, Maha Hassan, Fahad Alsharif, Naeem Chaudhri, Fahad Almohareb, Hazzaa Alzahrani, Mahmoud Aljurf
{"title":"Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia.","authors":"Amr Hanbali,&nbsp;Ahmed Kotb,&nbsp;Riad El Fakih,&nbsp;Feras Alfraih,&nbsp;Nahla Shihata,&nbsp;Walid Rasheed,&nbsp;Syed Osman Ahmed,&nbsp;Marwan Shaheen,&nbsp;Saud Alhayli,&nbsp;Ali Alahmari,&nbsp;Ahmad Alotaibi,&nbsp;Alfadel Alshaibani,&nbsp;Abdulwahab Albabtain,&nbsp;Mansour Alfayez,&nbsp;Maha Hassan,&nbsp;Fahad Alsharif,&nbsp;Naeem Chaudhri,&nbsp;Fahad Almohareb,&nbsp;Hazzaa Alzahrani,&nbsp;Mahmoud Aljurf","doi":"10.2217/ijh-2022-0005","DOIUrl":"https://doi.org/10.2217/ijh-2022-0005","url":null,"abstract":"<p><strong>Aim: </strong>The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the outcome of T-ALL/lymphoblastic lymphoma (LBL) AYA patients treated with pediatric protocols.</p><p><strong>Methods: </strong>A total of 35 T-ALL/LBL-AYA patients ages between 14 and 55 years were treated with AYA-15 protocol.</p><p><strong>Results: </strong>At a median follow-up of 5 years the overall survival, disease-free survival and event-free survival are 71%, 62% and 49.6% respectively. Toxicities were within the expected range.</p><p><strong>Conclusion: </strong>Our single-center experience real-world data in treating T-ALL/LBL-AYA patients with pediatric-inspired protocol demonstrates encouraging results of high survival rate and excellent tolerability for patients aged 18-55 years.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"12 1","pages":"IJH42"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/69/ijh-12-42.PMC9979159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10848654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Therapy-related core binding factor acute myeloid leukemia. 治疗相关核心结合因子急性髓性白血病。
International Journal of Hematologic Oncology Pub Date : 2023-02-01 DOI: 10.2217/ijh-2022-0004
Binsah George, Binoy Yohannan, Virginia Mohlere, Anneliese Gonzalez
{"title":"Therapy-related core binding factor acute myeloid leukemia.","authors":"Binsah George,&nbsp;Binoy Yohannan,&nbsp;Virginia Mohlere,&nbsp;Anneliese Gonzalez","doi":"10.2217/ijh-2022-0004","DOIUrl":"https://doi.org/10.2217/ijh-2022-0004","url":null,"abstract":"<p><p>Therapy-related acute myeloid leukemia (t-AML) usually stems from exposure of the bone marrow to cytotoxic chemotherapy and/or radiation therapy. t-AML is usually associated with poor overall survival, but occasionally t-AML can involve favorable-risk cytogenetics, including core binding factor AML (CBF-AML), which shows a recurrent chromosomal rearrangement with t(8;21) (q22;22) and 'inv(16) (p13.1;q22)/t(16;16)(p13.1;q22)', leading to '<i>RUNX1::RUNX1T1 and CBFB::MYH11</i>' fusion genes, respectively. Therapy-related CBF-AML (t-CBF-AML) accounts for 5-15% of CBF-AML cases and tends to have better outcomes than t-AML with unfavorable cytogenetics. Although CBF-AML is sensitive to high-dose cytarabine, t-CBF-AML has worse overall survival than <i>de novo</i> CBF- AML. The objective of this review is to discuss the available data on the pathogenesis, mutations, and therapeutic options in patients with t-CBF-AML.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"12 1","pages":"IJH43"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/bb/ijh-12-43.PMC9979104.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10848657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric-type follicular lymphoma: a short review. 儿科型滤泡性淋巴瘤:简要回顾。
International Journal of Hematologic Oncology Pub Date : 2022-11-01 DOI: 10.2217/ijh-2022-0003
Ahmed Alnughmush, Riad El Fakih, Shamayel Mohammed, Mahmoud Aljurf
{"title":"Pediatric-type follicular lymphoma: a short review.","authors":"Ahmed Alnughmush,&nbsp;Riad El Fakih,&nbsp;Shamayel Mohammed,&nbsp;Mahmoud Aljurf","doi":"10.2217/ijh-2022-0003","DOIUrl":"https://doi.org/10.2217/ijh-2022-0003","url":null,"abstract":"<p><p>Pediatric-type follicular lymphoma is an uncommon and newly recognized entity of lymphoid neoplasm commonly encountered in the young population. Despite its indolent clinical course and localized nodal involvement, it has been characterized by its high-grade histopathological features. The overlapping features between this disease and several entities have made approaching this unique entity significantly challenging, with all such features being reflected in the strict diagnostic criteria highlighted by the WHO 2016 lymphoid malignancy classification. Despite its characteristic high-grade histology, its cure rates have remained high, with relapse and transformation rarely occurring. Interestingly, several cases have achieved remission following nodal disease resection, possibly eliminating the need for chemotherapy and radiation and preventing long-term morbidities from later approaches in disease survivors.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"11 4","pages":"IJH41"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/0c/ijh-11-41.PMC9732916.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10367199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia. 土耳其现实生活数据:慢性髓性白血病的人口统计学特征、治疗结果和合并症的影响。
International Journal of Hematologic Oncology Pub Date : 2022-06-30 eCollection Date: 2022-06-01 DOI: 10.2217/ijh-2021-0008
Guray Saydam, Ali Unal, Ibrahim Celalettin Haznedaroglu, Abdullah Hacihanifioglu, Ozgur Mehtap, Erdal Kurtoglu, Mesut Gocer, Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Nil Guler, Basak Unver Koluman, Mehmet Sonmez, Nergiz Erkut, Emin Kaya, Irfan Kuku, Mehmet Ali Erkurt, Gulsum Ozet, Funda Ceran, Fahri Sahin, Nur Soyer, Meliha Nalcaci, Mehmet Yilmaz, Sirac Bozkurt, Birkan Aver, Begum Ozdengulsun, Egemen Ozbilgili, Osman Ilhan
{"title":"Turkey real-life data: demographic features, treatment results and effects of comorbidities in chronic myeloid leukemia.","authors":"Guray Saydam,&nbsp;Ali Unal,&nbsp;Ibrahim Celalettin Haznedaroglu,&nbsp;Abdullah Hacihanifioglu,&nbsp;Ozgur Mehtap,&nbsp;Erdal Kurtoglu,&nbsp;Mesut Gocer,&nbsp;Mehmet Turgut,&nbsp;Engin Kelkitli,&nbsp;Memis Hilmi Atay,&nbsp;Nil Guler,&nbsp;Basak Unver Koluman,&nbsp;Mehmet Sonmez,&nbsp;Nergiz Erkut,&nbsp;Emin Kaya,&nbsp;Irfan Kuku,&nbsp;Mehmet Ali Erkurt,&nbsp;Gulsum Ozet,&nbsp;Funda Ceran,&nbsp;Fahri Sahin,&nbsp;Nur Soyer,&nbsp;Meliha Nalcaci,&nbsp;Mehmet Yilmaz,&nbsp;Sirac Bozkurt,&nbsp;Birkan Aver,&nbsp;Begum Ozdengulsun,&nbsp;Egemen Ozbilgili,&nbsp;Osman Ilhan","doi":"10.2217/ijh-2021-0008","DOIUrl":"https://doi.org/10.2217/ijh-2021-0008","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.</p><p><strong>Materials & methods: </strong>Hospital records between 2005 and 2018 were retrospectively reviewed.</p><p><strong>Results: </strong>Of 861 CP-CML patients included, 31% had at least one comorbidity at diagnosis. Sex, cardiovascular disease status at diagnosis and molecular (at least major) and cytogenetic (partial and complete) responses were the independent predictors of survival.</p><p><strong>Conclusion: </strong>The response rates of CP-CML patients to the tyrosine kinase inhibitors were satisfactory. In addition to tolerability and side effect profiles of drugs, comorbidity status of patients should also be considered in treatment choice in CML patients.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"11 3","pages":"IJH40"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/82/ijh-11-40.PMC9453544.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40356307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy 黏附分子在多发性骨髓瘤肿瘤发生和靶向治疗中的作用
International Journal of Hematologic Oncology Pub Date : 2022-04-01 DOI: 10.2217/ijh-2021-0017
M. Bou Zerdan, L. Nasr, J. Kassab, Ludovic Saba, Myriam Ghossein, M. Yaghi, B. Dominguez, C. Chaulagain
{"title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy","authors":"M. Bou Zerdan, L. Nasr, J. Kassab, Ludovic Saba, Myriam Ghossein, M. Yaghi, B. Dominguez, C. Chaulagain","doi":"10.2217/ijh-2021-0017","DOIUrl":"https://doi.org/10.2217/ijh-2021-0017","url":null,"abstract":"Every day we march closer to finding the cure for multiple myeloma. The myeloma cells inflict their damage through specialized cellular meshwork and cytokines system. Implicit in these interactions are cellular adhesion molecules and their regulators which include but are not limited to integrins and syndecan-1/CD138, immunoglobulin superfamily cell adhesion molecules, such as CD44, cadherins such as N-cadherin, and selectins, such as E-selectin. Several adhesion molecules are respectively involved in myelomagenesis such as in the transition from the precursor disorder monoclonal gammopathy of undetermined significance to indolent asymptomatic multiple myeloma (smoldering myeloma) then to active multiple myeloma or primary plasma cell leukemia, and in the pathological manifestations of multiple myeloma.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46111946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia 慢性髓性白血病患者合并症对酪氨酸激酶抑制剂选择的影响
International Journal of Hematologic Oncology Pub Date : 2022-03-01 DOI: 10.2217/ijh-2021-0010
G. Saydam, R. Ali, A. Demir, A. E. Eşkazan, B. Guvenc, I. Haznedaroglu, M. Ozcan, O. Salim, M. Sonmez, A. T. Tuglular, M. Turgut, A. Unal, B. Aver, Sirac Bozkurt, Begum Ozdengulsun, O. Ilhan
{"title":"The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia","authors":"G. Saydam, R. Ali, A. Demir, A. E. Eşkazan, B. Guvenc, I. Haznedaroglu, M. Ozcan, O. Salim, M. Sonmez, A. T. Tuglular, M. Turgut, A. Unal, B. Aver, Sirac Bozkurt, Begum Ozdengulsun, O. Ilhan","doi":"10.2217/ijh-2021-0010","DOIUrl":"https://doi.org/10.2217/ijh-2021-0010","url":null,"abstract":"Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clinical approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient’s individual condition.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47743689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The use of hypomethylating agents in hematologic malignancies: treatment preferences and results 低甲基化药物在血液恶性肿瘤中的应用:治疗偏好和结果
International Journal of Hematologic Oncology Pub Date : 2021-11-12 DOI: 10.2217/ijh-2020-0019
I. Serin, M. Doğu
{"title":"The use of hypomethylating agents in hematologic malignancies: treatment preferences and results","authors":"I. Serin, M. Doğu","doi":"10.2217/ijh-2020-0019","DOIUrl":"https://doi.org/10.2217/ijh-2020-0019","url":null,"abstract":"Aim: The objective of this article was to compare the efficiency of azacitidine (AZA) and decitabine (DAC) in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not suitable for high-dose chemotherapy. Materials and methods: MDS and AML patients who were treated with hypomethylating agents (HMAs) between January 2005 and 2020 were evaluated retrospectively. Results: No statistically significant difference was found between the patients who received AZA or DAC in AML patients. In MDS group, the rate of patients who achieved remission was statistically significantly higher in patients who received DAC (p = 0.032). Conclusion: The advantage in terms of response for MDS and no survival difference between AZA and DAC for AML and MDS patients will be an important contribution to the literature.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46957957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron overload during the treatment of acute leukemia: pretransplant transfusion experience. 急性白血病治疗期间铁超载:移植前输血经验。
International Journal of Hematologic Oncology Pub Date : 2021-11-12 eCollection Date: 2021-09-01 DOI: 10.2217/ijh-2021-0005
Osman Yokus, Celalettin Herek, Tahir Alper Cinli, Hasan Goze, Istemi Serin
{"title":"Iron overload during the treatment of acute leukemia: pretransplant transfusion experience.","authors":"Osman Yokus,&nbsp;Celalettin Herek,&nbsp;Tahir Alper Cinli,&nbsp;Hasan Goze,&nbsp;Istemi Serin","doi":"10.2217/ijh-2021-0005","DOIUrl":"10.2217/ijh-2021-0005","url":null,"abstract":"<p><strong>Background: </strong>Recent studies have shown the increased risk of mortality in cases with acute leukemia and iron overload. We aimed to determine the status of iron overload in patients with acute leukemia.</p><p><strong>Materials & methods: </strong>Patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) between January 2015 and December 2019 were included in the study.</p><p><strong>Results: </strong>At 6 months, there were statistically more patients with serum ferritin >1000 in the AML group compared to the ALL group (p = 0,011).</p><p><strong>Conclusion: </strong>Iron overload occurs earlier in patients with AML; the difference disappears after 6 months of treatment. It is the correct point to emphasize that iron overload is an important factor of pretransplant morbidity, especially in AML cases.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"10 3","pages":"IJH36"},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/64/ijh-10-36.PMC8609998.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39673978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Phase I trial of talazoparib in patients with advanced hematologic malignancies. talazoparib在晚期血液恶性肿瘤患者中的I期临床试验。
International Journal of Hematologic Oncology Pub Date : 2021-10-22 eCollection Date: 2021-09-01 DOI: 10.2217/ijh-2021-0004
Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti
{"title":"A Phase I trial of talazoparib in patients with advanced hematologic malignancies.","authors":"Ajay K Gopal,&nbsp;Rakesh Popat,&nbsp;Ryan J Mattison,&nbsp;Tobias Menne,&nbsp;Adrian Bloor,&nbsp;Terry Gaymes,&nbsp;Asim Khwaja,&nbsp;Mark Juckett,&nbsp;Ying Chen,&nbsp;Matthew J Cotter,&nbsp;Ghulam J Mufti","doi":"10.2217/ijh-2021-0004","DOIUrl":"https://doi.org/10.2217/ijh-2021-0004","url":null,"abstract":"<p><strong>Aim: </strong>The objective of this study was to establish the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of talazoparib.</p><p><strong>Patients & methods: </strong>This Phase I, two-cohort, dose-escalation trial evaluated talazoparib monotherapy in advanced hematologic malignancies (cohort 1: acute myeloid leukemia/myelodysplastic syndrome; cohort 2: chronic lymphocytic leukemia/mantle cell lymphoma).</p><p><strong>Results: </strong>Thirty-three (cohort 1: n = 25; cohort 2: n = 8) patients received talazoparib (0.1-2.0 mg once daily). The MTD was exceeded at 2.0 mg/day in cohort 1 and at 0.9 mg/day in cohort 2. Grade ≥3 adverse events were primarily hematologic. Eighteen (54.5%) patients reported stable disease.</p><p><strong>Conclusion: </strong>Talazoparib is relatively well tolerated in hematologic malignancies, with a similar MTD as in solid tumors, and shows preliminary anti leukemic activity.Clinical trial registration: NCT01399840 (ClinicalTrials.gov).</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"10 3","pages":"IJH35"},"PeriodicalIF":0.0,"publicationDate":"2021-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39763145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信